Evaluation of the Mechanisms of Sarcopenia in Chronic Inflammatory Disease: Protocol for a Prospective Cohort Study

• Conditions: Chronic Liver Disease; Inflammatory Bowel Diseases; Rheumatoid Arthritis
• Interventions: Other: National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)

• Registration Number: NCT04734496
• Lead Sponsor: University of Birmingham

Brief Summary

Prospective, observational study to assess sarcopenia across three chronic inflammatory diseases: chronic liver disease, Inflammatory Bowel Disease, Rheumatoid Arthritis both before and after therapeutic intervention (standard of care treatment i.e. nutrition/exercise; biologic for IBD etc).

Detailed Description

Introduction: Several chronic inflammatory diseases co-exist with and accelerate sarcopenia (reduction in muscle strength, quantity and quality) and negatively impact on both morbidity and mortality. There is limited research on the extent of sarcopenia in such conditions, how to accurately assess it and whether there are generic or disease specific mechanisms driving sarcopenia.

Methods: This prospective cohort study is unique; it provides a multi-modal approach to assess sarcopenia across three chronic inflammatory diseases: chronic liver disease, Inflammatory Bowel Disease, Rheumatoid Arthritis both before and after therapeutic intervention. A total of 170 patients will be recruited (50 with Chronic liver disease, 20 with non-cirrhotic nonalcoholic fatty liver disease, 50 with Inflammatory Bowel Disease and 50 with Rheumatoid Arthritis) and including a comparison cohort of n=20 age-sex matched healthy individuals.

Participants will undergo 4 assessments at defined time points; weeks 0, 2, 12 and 24, with blood tests to assess endocrine and inflammatory status; anthropometric (hand grip strength; mid-arm muscle circumference; triceps skinfold thickness); functional testing (short physical performance battery and isokinetic dynamometry); imaging ( ultrasound and Magnetic Resonance Imaging of the quadriceps), and vastus lateralis muscle biopsy. Physical activity and sleep will be monitored using actigraphy, and quality of life via questionnaires. Food diaries for nutritional intake analysis will be sampled between 0-2, 12 and 24 weeks. Stool and urine samples will be sampled for future microbiome and metabolomics analysis, respectively.

This study will identify mechanisms across the groups and within each cohort, to further target interventions to reduce sarcopenia in the future. This is the first study to use a multi modal assessment to characterise sarcopenia in chronic disease. The multi-modal assessment includes serological, anatomical, functional and histological analyses to evaluate the deep phenotyping of these patients. The observational study of small sample sizes will allow potential future targets for intervention.

Study Timeline

• Study Start: 2019-01-01
• Primary Completion: 2020-04-01
• Status Verified: 2021-01
• Study First Submitted: 2021-01-18
• Study First Submitted QC: 2021-01-27
• Last Update Submitted: 2021-01-27
• Study First Posted: 2021-02-02
• Last Update Posted: 2021-02-02
• Study Completion: 2021-09-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

1. A formal confirmed diagnosis of their underlying chronic inflammatory condition:

   1. Inflammatory bowel disease cohort patients will have endoscopic or radiological evidence.

      Some of the Chronic liver disease cohort will have had a liver biopsy, serological and radiological confirmation will be sufficient.

   2. RA cohort, clinical, serological and radiological confirmation will be sufficient.

   3. Biologic therapy naïve on recruitment or commencing a new biologic if in the IBD or IA cohort.

2. Adults aged ≥ 18 years

3. Able to confirm written consent to the study

4. Biologic therapy naïve on recruitment or commencing a new biologic if in the IBD or RA cohort Pre-existing or current use of immunosuppressant agents or Disease Modifying Antirheumatic Drugs (DMARDs) are acceptable in all cohorts.

5. Meeting ACR (American College of Rheumatology) /EULAR (European League Against Rheumatism) 2010 or ACR 1987 Criteria for rheumatoid arthritis and starting DMARD therapy.

6. Meeting criteria of an inflammatory arthritis as per the American College of Rheumatology

7. Meeting criteria of liver cirrhosis including all Child Pugh scores from A-C as per British Association for the Study of the Liver guidance.

8. Meeting criteria for Inflammatory bowel disease as per the British Society of Gastroenterology guidance.

9. For muscle biopsy sampling (does not preclude patients from participating if they do not meet the below criteria) INR ≤ 1.6 Platelet count > 30

Exclusion Criteria

1. Refusal or lack capacity to give informed consent.

2. Currently enrolled in an interventional trial with active treatment for their chronic disease condition.

3. Previously undergone LT or biliary intervention in the Chronic liver disease cohort.

4. Underlying or active cancer.

5. Biliary intervention if Chronic liver disease

6. For Muscle biopsies only (able to continue in study):

   1. Obvious injury to both thighs.
   2. Active bleeding of site, pre-procedure,
   3. Abnormal observation parameters.
   4. Acute illness.
   5. INR > 1.6.
   6. Platelet count < 30.
   7. Anticoagulation which cannot be paused due to increased risk to pre-existing co-morbidity.

7. For undergoing an Magnetic resonance imaging (MRI)

   1. Pacemaker.
   2. Metal work inserted that is not MRI compatible or further information cannot be obtained.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Chronic Liver Disease	National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)	Patients with end-stage liver disease. Standard of care treatment will be nutrition and exercise as per European Association Study of Liver nutrition guidelines.
Rheumatoid Arthritis/Psoriatic arthropathy	National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)	Patients requiring biological therapy due to ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy
Inflammatory Bowel Disease	National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)	Patients with Crohns or Ulcerative Colitis with ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy

Primary Outcome Measures

Name	Time	Method
Sarcopenia (Muscle Area) using Magnetic Resonance Imaging	6 months	Vastus lateralis and rectus femoris muscle axial cross sectional assessment will be measured at 50% of femur length
Sarcopenia (Muscle Area) using ultrasound	6 months	Vastus lateralis and rectus femoris muscle axial cross sectional assessment will be measured at 50% of femur length.

Secondary Outcome Measures

Name	Time	Method
Handgrip strength	6 month	Both hands using handheld Dynamometer (North Coast Medical, Morgan Hill)
Muscle biopsy of the Vastus lateralis	6 month	Muscle structure using standardised haemotoxylin/eosin and immunohistochemistry
Quality of Life questionnaire	6 month	Short Form-36 health-related Quality of Life questionnaire (Quality Metric Health Outcomes Solutions, Lincoln, USA)
Leg (Quadricep/Hamstring) strength	6 month	Leg strength/power by Isokinetic Dynamometry - the patient will be asked to extend the leg as strong as possible and then to flex, for 5 repetitions

Trial Locations

Locations (1)

Institute of Inflammation and Ageing (IIA) University of Birmingham Research Laboratories; 🇬🇧 Birmingham, West Midlands, United Kingdom